N/A N=4 Dietary Soy Isoflavones In Chronic Pancreatitis
Chronic Pancreatitis
Primary: Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=102 Clinical Evaluation of Kerr SonicFill™ 2 vs 3M ESPE Filtek™ Supreme Ultra Universal Restorative
Dental Caries
Primary: Change in Esthetic Properties: Number of Teeth, Rated 1 (Most Desirable Outcome) to 5 (Least Desirable Outcome), in Each Esthetic Category — 25; 25; 2; 2 Teeth
N/A N=5,094 Second Survey of Intensive Care in India
Critical Illness
Primary: ICU Mortality — 1092 Participants
Phase 2 N=108 New Medication Treatment for Stimulant Dependence
Cocaine Dependence
Primary: Cocaine Use by Self-report — 67; 67 Percent of cocaine-free (abstinent)days — p=0.972
Phase 2 N=85 Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity
Primary: Change From Baseline in Total Attention-Deficit Hyperactivity Disorder Rating Scale IV (ADHD-RS-IV) Score — -16.2; -7.9 score on a scale — p=<0.001
N/A N=1,754 Evaluation of a Diagnostic to Identify Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Brazil
G6PD Deficiency
Primary: Sensitivity of SD Biosensor STANDARD G6PD Test for Identifying G6PD Deficient Individuals — 100.0; 100.0 percentage of participants
Phase 3 N=991 A Study of SI-6603 in Patients With Lumbar Disc Herniation
Intervertebral Disc Disease · Lumbar Disc Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAE) — 615 Participants
N/A N=1,150 Randomized Endo-Vein Graft Prospective
Coronary Artery Bypass Grafting
Primary: Incidence of First MACE During Active Follow-up Period. — 80; 89 Participants — p=0.47
N/A N=136 Mechanisms of Active Music Engagement to Improve Health Outcomes of Children With Cancer and Parents
Cancer
Primary: Family Normalcy Perspective - Family Management Measure (FaMM) — 35.3; 36.2; 34.8; 34.3 score on a scale
Phase 1 N=48 Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)
Actinic Keratoses
Primary: Assessment of Baseline-adjusted Plasma Concentration-time Curves for ALA After a Single PDT Treatment Applying 3 Tubes of BF-200 ALA in Conjunction With the BF-RhodoLED®…
Phase 1 N=20 Vascepa to Accelerate Lipoprotein Uptake and Elimination
Lipid Disorder · Triglycerides High · Dyslipidemias
Primary: Change in VLDL-apoB100 Production Rate — 21.7; 14.9; 21.3; 17.2 mg VLDL apoB100 / kg body weight per day — p=0.65
N/A N=167 Psychotherapy for Anxiety in Children With Autism Spectrum Disorder
Autism Spectrum Disorders · Autism · Asperger's Syndrome
Primary: Change From Baseline in Anxiety Severity on the Pediatric Anxiety Rating Scale After 16 Weeks of Treatment. — 3.43; 3.47; 3.28; 2.13 units on a scale
N/A N=9 Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp
Type 1 Diabetes Mellitus
Primary: Test the Safety of the AP Device While the Subject is Under Close Medical Supervision in the Clinical Research Center (CRC) Setting. — 81.6 percentage time in range (70…
N/A N=108 Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking
Co-Occurring Disorders · Homelessness · Substance Abuse Disorder
Primary: Number of MISSION Sessions Undertaken — 0; 574 number of MISSION Sessions
Phase 2 N=16 A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer
Breast Cancer
Primary: Adiponectin — 1308 pg/ml